依达拉奉治疗急性中重型颅脑创伤40例疗效观察

目的观察依达拉奉对急性中、重型颅脑创伤患者的治疗效果。方法将80例急性颅脑创伤患者随机分为依达拉奉组(治疗组)和常规治疗组(对照组),每组40例。对照组予以常规治疗,包括脱水、抗感染、激素以及依手术指征清除颅内血肿、去骨瓣减压等治疗。治疗组在对照组基础上加用依达拉奉30mg 5%葡萄糖溶液100ml静脉滴注,30min内滴完,2次/d,共14d。根据格拉斯哥昏迷评分(GCS)、脑水肿程度以及格拉斯哥结果分级(GOS)评估等比较两组患者病情恢复情况。结果(1)两组患者治疗前、后GCS评分间差异均有统计学意义(P<0·05);组间比较,两组患者治疗7d、14d后GCS评分间差异均有统计学意义(P<0·05)。(2)治疗10d后两组患者脑水肿程度间差异有统计学意义(P<0·01)。(3)两组患者GOS评估情况间差异有统计学意义(P<0·05)。结论急性中、重型颅脑创伤应用依达拉奉,可降低颅脑创伤后的病残程度,促进脑神经功能恢复,减轻脑水肿,且不良反应小、安全性高,值得推广使用。

Effect of Edaravone on Patients with Acute Moderate and Severe Brain Injury

Objective To evaluate the efficacy and safety of Edaravone on the patients with acute moderate and severe brain injury.Methods Totally 80 patients with acute moderate and severe brain injury were divided into trial group and control group randomly,with 40 cases in each.Both group were received the standard therapy,meanwhile the patients in the trial group were given Edaravone infusion at a dose of 30 mg,twice a day,for 14 days.According to GCS,degree of cerebral edema and GOS,the recovery conditions of the patients between two groups were compared.Results There was a significant difference in GCS before and after treatment in the two groups (P<0.05);there were also significant differences in GCS 7 days and 14 days after treatment between the two groups (P<0.05).There was a significant difference in brain edema 10 days after treatment between the two groups (P<0.01).The difference in GOS between the two groups was found to be statistically significant (P<0.05).Conclusion The early application of Edaravone for patients with acute moderate and server brain injury can decrease the degree of disability,promote the recovery of neural function,and reduce brain edema,with a quite reliable safety.